Asheville, NC

Digestive Health Partners

Ulcerative Colitis

Colorectal Cancer

Crohn Disease

Liver Cancer

Hepatocellular Carcinoma

Hepatitis B

Fibrosis

Tofacitinib

Vedolizumab

Mirikizumab

Exact Sciences Corporation

Guardant Health

Janssen (J&J Innovative Medicine)

Lilly

Takeda

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and severe ulcerative colitis (UC). Another aim is to learn about treatment with Vedolizumab alone after the double treatment.

All participants will receive vedolizumab together with tofacitinib for 8 weeks and will be checked for response. Participants who show a response to the treatment after 8 weeks will be treated with vedolizumab alone for an additional 44 weeks.

Each participant will be followed up for at least 26 weeks after the last dose of vedolizumab.

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Digestive Health Partners | Asheville, NC

Site insights

Work at this site?

Active trials

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Trial sponsors